EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring the Pyrimidine Scaffold for the Development of SARS-CoV-2 M pro Inhibitors

Salvatore Nieddu, Giuseppe Ruggieri iD, Riccardo De Santis, Paolo Malune, Elisa Patacchini iD, Valentina Noemi Madia iD, Francesco Saccoliti iD, Antonella Messore iD, Laura Zarbo iD, Angela Corona iD, Donatella Amatore, Giorgia Grilli und 6 weitere

ACS Infectious Diseases · 11.09.2026 · 12 (9) · 3253-3264

DOI: 10.1021/acsinfecdis.6c00583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 07.08.2026. Verfasst von Salvatore Nieddu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life and Environmental Sciences, Cittadella Universitaria di Monserrato, University of Cagliari, Cagliari, MonserratoSS-554, Italy. Hauptthemen laut MEDLINE: Pyrimidines, SARS-CoV-2, Antiviral Agents, Protease Inhibitors. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sapienza Universit? di Roma, Ministero dell'Universit? e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still a major public health issue, even today. Among the SARS-CoV-2 nonstructural proteins, the main protease (Mpro) plays a critical role in viral polyprotein processing and is therefore indispensable for viral replication. For this reason, it represents one of the most promising therapeutic targets for the development of antiviral agents against SARS-CoV-2. Currently, only one protease antiviral agent (nirmatrelvir) has received emergency approval for COVID-19 treatment, the disease caused by SARS-CoV-2 infection. However, the emergence of viral mutations may compromise its efficacy, highlighting the urgent need to develop new, safe, and effective protease antiviral agents. In the present work, we designed and synthesized new SARS-CoV-2 Mpro small-molecule inhibitors endowed with a pyrimidine scaffold. A series of derivatives were evaluated in both biochemical and cell-based assays to assess their antiviral efficacy, with some of them being able to inhibit the SARS-CoV-2 Mpro activity and to suppress viral replication. Docking studies were confirmed by site-directed mutagenesis, and the mechanism of action of the most promising compound was elucidated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesSARS-CoV-2Antiviral AgentsProtease InhibitorsCoronavirus 3C ProteasesViral Nonstructural ProteinsBetacoronavirusHumansMolecular Docking SimulationVirus ReplicationAnimalsCOVID-19 Drug TreatmentDrug DesignVero Cells

Stichwörter der Autor:innen

COVID-19SARS-CoV-2drug designmain proteasepyrimidine derivativessmall molecules

Substanzen

PyrimidinesAntiviral AgentsProtease InhibitorsCoronavirus 3C ProteasesViral Nonstructural Proteinspyrimidine

Autor:innen und Institutionen

  • Department of Life and Environmental Sciences, Cittadella Universitaria di Monserrato, University of Cagliari, Cagliari, MonserratoSS-554, Italy.
  • Department of Chemistry and Pharmaceutical Technologies, Istituto Pasteur-Fondazione Cenci Bolognetti, "Sapienza" Università di Roma, P. le Aldo Moro 5, RomeI-00185, Italy.
  • Department of Public Health, Experimental Medicine and Forensic, University of Pavia, Pavia27100, Italy.
  • Defence Institute for Biomedical Sciences, via di Villa Fonseca 6, Rome00184, Italy.
  • Department of Public Health and Infectious Diseases, "Sapienza" Università di Roma, p.Le Aldo Moro, 5, Rome00185, Italy.
  • Department of Science, Roma Tre University, Viale Guglielmo Marconi 446, Rome00146, Italy.

ORCID-Profile: Giuseppe Ruggieri, Elisa Patacchini, Valentina Noemi Madia, Francesco Saccoliti, Antonella Messore, Laura Zarbo, Angela Corona, Roberta Costi, Roberto Di Santo, Francesca Esposito

Förderung

  • Sapienza Universit? di Roma
  • Ministero dell'Universit? e della Ricerca

Zitieren

APA

Nieddu, S., Ruggieri, G., De Santis, R., Malune, P., Patacchini, E., Madia, V. N., Saccoliti, F., Messore, A., Zarbo, L., Corona, A., Amatore, D., Grilli, G., Amoroso, A., Lista, F., Tramontano, E., Costi, R., Di Santo, R., & Esposito, F. (2026). Exploring the Pyrimidine Scaffold for the Development of SARS-CoV-2 M pro Inhibitors. ACS Infectious Diseases, 12(9), 3253-3264. https://doi.org/10.1021/acsinfecdis.6c00583

Vancouver

Nieddu S, Ruggieri G, De Santis R, Malune P, Patacchini E, Madia VN, et al. Exploring the Pyrimidine Scaffold for the Development of SARS-CoV-2 M pro Inhibitors. ACS Infectious Diseases. 2026;12(9):3253-3264. doi:10.1021/acsinfecdis.6c00583

BibTeX
@article{Nieddu2026,
  author = {Nieddu, Salvatore and Ruggieri, Giuseppe and De Santis, Riccardo and Malune, Paolo and Patacchini, Elisa and Madia, Valentina Noemi and Saccoliti, Francesco and Messore, Antonella and Zarbo, Laura and Corona, Angela and Amatore, Donatella and Grilli, Giorgia and Amoroso, Alessandra and Lista, Florigio and Tramontano, Enzo and Costi, Roberta and Di Santo, Roberto and Esposito, Francesca},
  title = {Exploring the Pyrimidine Scaffold for the Development of SARS-CoV-2 M pro Inhibitors},
  journal = {ACS Infectious Diseases},
  year = {2026},
  volume = {12},
  number = {9},
  pages = {3253--3264},
  doi = {10.1021/acsinfecdis.6c00583}
}
Kostenlos starten →